MRO Magazine

AdvanSource Biomaterials Engages Mirus Securities Inc. as Its Strategic Advisor


December 3, 2015
By Business Wire News

WILMINGTON, Mass.

AdvanSource Biomaterials Corporation (OTCQB:ASNB), a leading developer of advanced polymer materials for a broad range of medical devices, today announced the engagement of Mirus Securities Inc. (“Mirus”). Mirus, an investment bank located in the metropolitan Boston area with in-depth experience within the med-tech manufacturing space, has been engaged for the purpose of providing guidance and assessing strategic alternatives.

About Mirus Securities Inc.

Mirus Securities Inc. is a subsidiary of Mirus Capital Advisors which provides investment banking solutions to corporations and business owners in the health care, technology, business services, manufacturing, consumer products, and resort and hospitality industries. Since 1987, Mirus has provided corporate finance advisory services on engagements including mergers, acquisitions, divestitures, recapitalizations and valuations. More information about Mirus Securities, Inc. and Mirus Capital Advisors may be found at www.merger.com.

About AdvanSource Biomaterials Corporation

AdvanSource Biomaterials Corporation manufactures advanced polymer materials, which provide critical characteristics in the design and development of medical devices. The Company’s biomaterials are used in devices that are designed for treating a broad range of anatomical sites and disease states. AdvanSource’s business model leverages its proprietary materials science technology and manufacturing expertise in order to expand its product sales and royalty and license fee income. More information about AdvanSource is available at its website at www.advbiomaterials.com.

Forward-Looking Statements

AdvanSource Biomaterials Corporation believes that this press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could cause results to differ materially from the forward-looking statements. For further information on such risks and uncertainties, you are encouraged to review the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended March 31, 2015 and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2015. The Company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments, except as required by law.

For AdvanSource Biomaterials Corporation
CLV Communications
David Volpe, 508-523-3141
david@clvllc.com